There are 3163 resources available
330P - Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients
Presenter: Shereef Elsamany Mohammed
Session: Poster session 14
331P - Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
Presenter: Mingxia Jiang
Session: Poster session 14
332P - Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab plus nab-paclitaxel followed by epirubicin/cyclophosphamide for TNBC: A phase II TREND trial
Presenter: yingying Xu
Session: Poster session 14
334P - Cardiovascular events related to CDK4/6 inhibitors: A systematic review and safety meta-analysis of randomized controlled trials
Presenter: Louis Boismoreau
Session: Poster session 14
335P - First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 14
336P - Determination of the most common hereditary mutations associated with breast cancer and ovarian cancer in the population of Ukrainian women
Presenter: Dmytro Nehrulia
Session: Poster session 14
337P - Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?
Presenter: Jennifer Chen
Session: Poster session 14
338TiP - EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Presenter: Michail Ignatiadis
Session: Poster session 14
339TiP - A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Presenter: Theodoros Foukakis
Session: Poster session 14